Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis

Author(s): Alberto Lazaro, Gloria Alvarez-Llamas, Julio Gallego-Delgado, Fernando de la Cuesta, Julio Osende, Ma Eugenia G. Barderas, Fernando Vivanco

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Volume 9 , Issue 2 , 2009

Become EABM
Become Reviewer


Proteomics applications to study the molecular effects of drug administration (pharmacoproteomics) on left ventricular hypertrophy (LVH) and atherosclerosis are here reviewed. In most cases, an absence of complete normalization after treatment is revealed, in contrast to what is reported by classical approaches.

Keywords: Atherosclerosis, cardiac hypertrophy, proteomics, pharmacoproteomics

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [141 - 148]
Pages: 8
DOI: 10.2174/187152909788488672
Price: $65

Article Metrics

PDF: 7